Boehringer Ingelheim GmbH 보도자료
ESC Congress 2016 Late Breaking Science Registry
08월 30일 19:15
First outcome results from the GLORIA™-AF Registry show that treatment with dabigatran etexilate was associated with low incidences of stroke, major bleeding and lif...
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice
08월 16일 13:35
Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate).[1,2] ...
The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe
07월 20일 17:35
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. It is also a great challenge for the medical personnel treating th...
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
07월 15일 10:25
Scotland--(BUSINESS WIRE)-- Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class of ...
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
07월 14일 13:40
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of B...
INMARK™ now enrolling: first study to evaluate the effect of OFEV® (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients
06월 30일 18:10
Boehringer Ingelheim today announces that the first patient has been enrolled in a new study, INMARK™, investigating the effect of OFEV® (nintedanib) on changes in s...
Jardiance® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
06월 15일 11:45
New data showed Jardiance® (empagliflozin) reduced the risk for new-onset or worsening kidney disease by 39 percent versus placebo when added to standard of care in ...
New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
06월 13일 11:50
New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® (empagliflozin) compared ...
New study results show Trajenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment
06월 13일 10:50
Results from the MARLINA-T2DTM trial demonstrated that Trajenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli Lilly and Company, reduced blood su...
Boehringer Ingelheim and Harvard scientists establish a research alliance to find novel treatments for severe fibrotic diseases
06월 08일 09:55
Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute’s - Harvard Fibrosis Network to discover new wa...
New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound
06월 07일 11:45
Boehringer Ingelheim will announce updated results from the Phase II part of the HM-EMSI-101 [NCT01588145] trial at the Annual Meeting of the American Society of Cli...
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadly investigate promising lung cancer compound olmutinib
06월 03일 11:50
Boehringer Ingelheim has initiated the ELUXA trial programme, designed to further investigate the therapeutic potential of olmutinib* (BI 1482694 / HM61713), a novel...
Boehringer Ingelheim and Inventiva collaborate to develop potential new treatments for idiopathic pulmonary fibrosis
05월 31일 18:45
Boehringer Ingelheim and Inventiva, a French biopharmaceutical company specialised in the development of innovative therapies for fibrosis, oncology and orphan disea...
3 out of 4 people with symptomatic asthma report reduced productivity at work
05월 27일 13:05
Not for distribution to UK/US/Canadian media Results were released today by Boehringer Ingelheim from an international survey, providing new insight into the nega...
IL-23 inhibitor risankizumab induces remission in Phase II study in patients with moderate-to-severe Crohn’s disease
05월 25일 11:00
Results were presented today from a proof-of-concept, Phase II, randomized, placebo-controlled study (NCT02031276) in Crohn’s disease with investigational biologic, ...
1 2 3 4 5 6 7 8 9 10 11 >
Boehringer Ingelheim GmbH
상장여부 : 비상장
본사 소재지 : INGELHEIM, Germany
업종: 건강-제약
기업 개요:
등록된 회사소개가 없습니다.